Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 3/20 | 0.42 |
| ▸ | CES2 | O00748 | 3/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15651 | 0.95 | CES1 (0.49) | CES1CES2SRCL3MBTL1KMT2A | |
| Methane SCHEMBL16506198 | 0.94 | CES1 (0.47) | CES1CES2SRCL3MBTL1KMT2A | |
| Water SCHEMBL28127793 | 0.94 | CES1 (0.47) | CES1CES2SRCL3MBTL1KMT2A | |
| SCHEMBL4591841 | 0.91 | CES1 (0.47) | CES1CES2SRCLMNANAAA | |
| SCHEMBL8083975 | 0.89 | CES1 (0.47) | CES1CES2SRCNAAA | |
| Pyrrole SCHEMBL27588201 | 0.88 | CES1 (0.43) | CES1CES2SRCL3MBTL1KMT2A | |
| Dibenzoylmethane SCHEMBL2905077 | 0.88 | KMT2A (0.49) | CES1ALDH1A1CES2SRCHPGD | |
| SCHEMBL19031192 | 0.87 | MAPT (0.54) | CES1ALDH1A1ELANESRCLMNA | |
| SCHEMBL21239897 | 0.86 | CES1 (0.41) | CES1CES2SRCL3MBTL1KMT2A | |
| SCHEMBL19717693 | 0.85 | CES1 (0.40) | CES1ALDH1A1CES2SRCL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252154-B1 | METHOD FOR MINIMIZING THE CYTOTOXICITY OF THE EFFECTIVE AGENT IN A COMPOSITION THAT IS ADMINISTERED TO A MAMMAL OR GETS INTO CONTACT WITH A MAMMAL | OY GRANULA AB LTD (FI) | 2016-01-27 | — | — | EP | disclosed |
| US-8496974-B2 | Method for preparing a composition comprising a compound mixture and a carrier agent | OY GRANULA AB LTD (FI) | 2013-07-30 | — | — | US | disclosed |
| US-8414933-B2 | Brassocattleya marcella koss orchid extract and use thereof as skin depigmentation agent | L V M H RECHERCHE (FR) | 2013-04-09 | — | — | US | disclosed |
| US-8293287-B2 | Use of a Brassocattleya marcella Koss orchid extract as an active agent to prevent or delay the appearance of signs of cutaneous aging | L V M H RECHERCHE (FR) | 2012-10-23 | — | — | US | disclosed |
| EP-2252154-A2 | METHOD FOR MINIMIZING THE CYTOTOXICITY OF THE EFFECTIVE AGENT IN A COMPOSITION THAT IS ADMINISTERED TO A MAMMAL OR GETS INTO CONTACT WITH A MAMMAL | Oy Granula AB LTD (FI) | 2010-11-24 | — | — | EP | disclosed |
| US-20100129304-A1 | METHOD FOR PREPARING A COMPOSITION COMPRISING A COMPOUND MIXTURE AND A CARRIER AGENT | OY GRANULA AB LTD (FI) | 2010-05-27 | — | — | US | disclosed |
| US-20090258093-A1 | Use of a brassocattleya marcella koss orchid extract as an active agent to prevent or delay the appearance of signs of cutaneous aging | L.V.M.H. RECHERCHE | 2009-10-15 | — | — | US | disclosed |
| US-20090232758-A1 | Brassocattleya marcella koss orchid extract and use thereof as skin depigmentation agent | L V M H RECHERCHE | 2009-09-17 | — | — | US | disclosed |
| WO-2009101261-A2 | METHOD FOR MINIMIZING THE CYTOTOXICITY OF THE EFFECTIVE AGENT IN A COMPOSITION THAT IS ADMINISTERED TO A MAMMAL OR GETS INTO CONTACT WITH A MAMMAL | OY GRANULA AB LTD (FI) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100129304-A1 | METHOD FOR PREPARING A COMPOSITION COMPRISING A COMPOUND MIXTURE AND A CARRIER AGENT | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, BAK1, PMAIP1 | CES1 1093/4885ALDH1A1 2281/4885PPARA 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.